Mallinckrodt announces u.s. fda filing acceptance of new drug application treatment of hepatorenal syndrome

Mallinckrodt announces u.s. food and drug administration (fda) filing acceptance of new drug application for terlipressin for treatment of hepatorenal syndrome type 1 (hrs-1).mallinckrodt - anticipates fda advisory committee meeting to discuss submission later in 2020 for terlipressin.mallinckrodt plc - fda assigned a pdufa target date of september 12, 2020 for terlipressin.
MNK Ratings Summary
MNK Quant Ranking